{
    "nct_id": "NCT03708328",
    "official_title": "An Open Label, Multicenter, Dose Escalation and Expansion, Phase 1 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Patients With Advanced and/or Metastatic Solid Tumors",
    "inclusion_criteria": "General Inclusion Criteria:\n\n* Part A: Patient must have histologically or cytologically confirmed advanced and/or metastatic solid tumor malignancies for which standard curative or palliative measures do not exist, are no longer effective, or are not acceptable to the patient\n* Eastern Cooperative Oncology Group Performance Status 0-1\n* Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1)\n* Fresh biopsies may be required\n* Negative HIV, hepatitis B, or hepatitis C test result\n* Women of childbearing potential and male participants must agree to remain abstinent or use contraceptive methods as defined by the protocol\n\nAdditional Specific Inclusion Criteria for Participants with Melanoma:\n\n* Histologically confirmed, unresectable stage III or stage IV melanoma\n* Previously treated with approved anti-programmed death-ligand 1 (PD-L1)/anti-programmed death-1 (PD-1) agents with or without approved anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) therapy and up to one additional treatment regimen\n\nAdditional Specific Inclusion Criteria for Participants with Non-small Cell Lung Cancer (NSCLC) who Previously Received Treatment for Metastatic Disease:\n\n* Histologically confirmed advanced NSCLC\n* Previously treated with approved PD-L1/PD-1 inhibitors and platinum-based chemotherapy\n* Not more than 2 prior lines of treatment for metastatic disease are allowed prior to enrolling to the study\n* Participants must have experienced initial clinical benefit (stable disease or better) from most recent checkpoint inhibitor (CPI) therapy\n* Tumor PD-L1 expression as determined by immunohistochemistry assay of archival tumor tissue or tissue obtained at screening\n\nAdditional Specific Inclusion Criteria for Participants with Non-small Cell Lung Cancer (NSCLC) who Previously Did Not Receive Treatment for Metastatic Disease:\n\n* Histologically confirmed advanced NSCLC\n* Tumor PD-L1 expression as determined by immunohistochemistry assay of archival tumor tissue or tissue obtained at screening\n\nAdditional Specific Inclusion Criteria for Participants with Small Cell Lung Cancer (SCLC):\n\n* Histologically confirmed SCLC\n* Participants may have had prior chemotherapy, radiation therapy, or declined approved therapies for SCLC\n\nAdditional Specific Inclusion Criteria for Participants with Esophageal Squamous Cell Carcinoma (ESCC):\n\n* Participants whose major lesion was histologically confirmed as squamous cell carcinoma or adenosquamous cell carcinoma of the esophagus\n* Patients who have previously received not more than 1 prior line of treatment for metastatic disease prior to enrolling to the study\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "General Exclusion Criteria:\n\n* Pregnancy, lactation, or breastfeeding\n* Known hypersensitivity to any of the components of RO7121661\n* Active or untreated central nervous system (CNS) metastases\n* An active second malignancy\n* Evidence of concomitant diseases, metabolic dysfunction, physical examination findings, or clinical laboratory findings giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the participant at high risk from treatment complications\n* Known active or uncontrolled bacterial, viral, fungal, mycobacterial, parasitic, or other infection\n* Treatment with oral or IV antibiotics within 2 weeks prior to Cycle 1 Day 1\n* Active or history of autoimmune disease or immune deficiency\n* Prior treatment with adoptive cell therapies, such as CAR-T therapies\n* Concurrent therapy with any other investigational drug <28 days or 5 half-lives of the drug, whichever is shorter, prior to the first RO7247669 administration\n* Regular immunosuppressive therapy\n* Radiotherapy within the last 4 weeks before start of study drug treatment, with the exception of limited palliative radiotherapy\n* Prior treatment with a T-cell immunoglobulin and mucin domain-3 (TIM-3) inhibitor\n\nAdditional Specific Exclusion Criteria for Participants with NSCLC who Previously Received Treatment for Metastatic Disease:\n\n- Patients with the following mutations, rearrangements, translocations are not eligible: epidermal growth factor receptor (EGFR); anaplastic lymphoma kinase (ALK); ROS proto-oncogene 1 (ROS1), BRAFV600E, and neurotrophic receptor tyrosine kinase (NTRK)\n\nAdditional Specific Exclusion Criteria for Participants with NSCLC who Did Not Previously Receive Treatment for Metastatic Disease:\n\n* Prior therapy for metastatic disease\n* Adjuvant anti-PD-1 or anti-PD-L1 therapy\n\nAdditional Specific Exclusion Criteria for Participants with Small-Cell Lung Cancer (SCLC):\n\n- Prior therapy with any immune CPIs (such as anti-PD-L1/PD-1, CTLA-4)\n\nAdditional Specific Exclusion Criteria for Participants with Esophageal Squamous Cell Carcinoma (ESCC):\n\n- Prior therapy with any immunomodulatory agents",
    "miscellaneous_criteria": ""
}